The distributor docked Mr. Tyler’s pay after activist investors urged it to reflect its opioid settlements in executive pay appraisals.
McKesson is one of four drug companies in talks with states to resolve claims about their role in the opioid epidemic for a combined payout of more than $26 billion. It is the only one to decrease executive pay due to that settlement’s expected costs.
